What Are rBST-Treated Cows and Is Their Milk Safe?

Milk from cows treated with recombinant bovine somatotropin (rBST) is considered safe for human consumption by the U.S. Food and Drug Administration, which approved the hormone for commercial use in 1994. rBST is a lab-made copy of a growth hormone that cows produce naturally, and it boosts milk production when injected. The safety debate, though, has never been simple: it touches on everything from trace hormone levels in milk to animal welfare to the psychology of food labeling, and different countries have reached starkly different regulatory conclusions about whether the trade-offs are worth it.

How rBST Works in Dairy Cows

Cows naturally produce bovine somatotropin (bST), a protein hormone secreted by the pituitary gland that helps regulate growth and milk production. In the 1980s, scientists used recombinant DNA technology to produce a synthetic version of this hormone in bacteria, creating rBST (also called rbGH, for recombinant bovine growth hormone). When injected into lactating cows, rBST amplifies the signals that drive milk synthesis. Prolonged administration at different stages of lactation increases milk yield by boosting mammary blood flow, which in turn increases the amount of glucose the udder takes up and the amount of lactose it produces.¹ The net effect is that treated cows can produce meaningfully more milk per day than they otherwise would, which is why the technology was attractive to dairy producers in the first place.

Commercial rBST in the United States was sold under the brand name Posilac. It was typically administered as a slow-release injection every two weeks. The product was rapidly adopted by many dairy producers after approval because it improved both milk yield and feed efficiency, meaning each gallon of milk required less feed to produce.²

Does rBST Change the Milk Itself?

This is the question most people really want answered when they see “rBST-free” on a milk carton. The research here paints a nuanced picture. A detailed compositional study found that milk from rBST-treated cows showed shifts in its fatty acid profile, trending slightly toward less saturated fat and more monounsaturated fatty acids. The treated-cow milk also had somewhat less calcium and potassium but more lactose and protein than untreated milk.³ So on a molecular level, rBST treatment does leave a measurable fingerprint on milk composition.

Whether those differences matter to someone drinking the milk is another question entirely. A separate survey of retail milk found no meaningful differences in fatty acid composition between conventional milk and milk labeled rBST-free, and concluded that all of these milks were similar in nutritional quality and wholesomeness.⁴ The distinction matters: one study measured raw milk straight from treated versus untreated cows and found detectable differences, while the other looked at milk as it reaches consumers in stores and found the differences had essentially vanished. Processing, pooling milk from multiple farms, pasteurization, and normal variation among herds all blur whatever compositional shifts rBST treatment creates at the individual-cow level.

The IGF-1 Question

The most persistent safety concern about rBST milk centers not on the hormone itself but on insulin-like growth factor 1 (IGF-1), a naturally occurring protein in both cow and human bodies. Cows treated with rBST produce milk with elevated IGF-1 levels. Research has confirmed this increase and even used it as a way to identify which cows received the hormone.⁵⁶

Why does this matter? Epidemiological research has found a positive association between higher circulating IGF-1 levels in humans and several cancers, including breast, colorectal, and prostate cancer.⁷ That association is what fuels concern about consuming milk with elevated IGF-1. Some researchers have argued that IGF-1 can be absorbed from the gastrointestinal tract, pointing to growth-promoting effects observed in animal studies, and have suggested that absorption could be even higher in infants.⁸

The counterargument, and the one that U.S. regulators have relied on, is that the IGF-1 increase in rBST milk is small compared to the IGF-1 your own body produces every day. Human saliva and breast milk contain IGF-1 at levels comparable to or higher than what shows up in cow’s milk. Pasteurization also degrades some of the IGF-1 present. The FDA and others have concluded that milk from rBST-treated cows does not meaningfully increase a person’s overall IGF-1 exposure.⁹ This is one of those areas where the evidence genuinely supports both sides’ talking points, and your comfort level may depend on which part of the picture you weight more heavily.

What About Antibiotic Residues?

A common worry goes like this: rBST makes cows more prone to udder infections, which means more antibiotic use, which means more antibiotic residues in milk. The logic sounds plausible, but the evidence does not support the final link in the chain. A review of the literature found no evidence that rBST use has increased human exposure to antibiotic residues in milk.⁹ All commercially sold milk in the United States is tested for antibiotic residues before it reaches consumers, and tanker loads that test positive are discarded regardless of whether the source herd used rBST.

Researchers have also modeled the more indirect concern: could rBST-driven antibiotic use in cows breed resistant bacteria that end up causing human illness through the dairy beef supply? A quantitative risk assessment tracking several common foodborne bacteria found the risk to be negligible, with all scenarios predicting far less than one additional human illness per billion people per year.¹⁰ The model was deliberately designed to overestimate risk, and even so, the numbers came out vanishingly small.

Animal Health and Welfare

Where the evidence gets harder to dismiss is on the animal welfare side. A large meta-analysis found that rBST increased the risk of clinical mastitis (a painful udder infection) by about 25% during the treatment period.¹¹ Individual studies have shown mixed results on this point; one trial of a sustained-release formulation found no association between treatment and mastitis incidence.¹² But the pooled data tilts toward a real increase in infection risk.

The same meta-analysis found other welfare impacts that are harder to wave away:

Lameness: Treated cows had roughly a 55% increase in the risk of developing clinical lameness.
Fertility: The risk of failing to conceive rose by about 40%, and cows averaged about five extra days between calving and their next pregnancy.
Twinning: The data on whether rBST increased twinning risk was equivocal.

These findings were echoed by individual trials showing increased lameness in some treatment groups and delayed conception, though the severity varied by dose and management conditions.¹³ Proponents argue that these effects are manageable in well-run dairies, while critics see them as reason enough to ban the practice, which is exactly the split that has played out on the global regulatory stage.

Why Some Countries Banned It and the U.S. Did Not

The regulatory divide on rBST is stark. The United States approved it in 1994 and has maintained that approval, with the FDA concluding that milk from treated and untreated cows is indistinguishable in terms of safety. Canada, the European Union, Australia, New Zealand, and Japan all declined to approve rBST, though their stated reasons varied. Some focused primarily on the animal welfare evidence, while others cited the precautionary principle regarding long-term human health effects that had not been conclusively ruled out.

The EU’s scientific committee was particularly focused on the mastitis and lameness data, concluding that the animal welfare concerns alone were sufficient grounds for a ban. Canada reached a similar conclusion. Japan conducted its own economic analysis and found that rBST approval would accelerate consolidation in its dairy industry, disproportionately harming smaller farms while benefiting larger operations, which added an economic argument against approval.¹⁴

These different conclusions were not necessarily about different science. They reflected different regulatory philosophies about how much uncertainty is acceptable, whose welfare counts (human consumers, animals, small farmers), and whether proven production benefits justify proven welfare costs.

The “rBST-Free” Label and What It Actually Means

Walk down the dairy aisle in the United States and you will see “rBST-free” or “from cows not treated with rBST” on many cartons. The FDA has required that any product making this claim also carry a disclaimer stating that no significant difference has been shown between milk from rBST-treated and non-rBST-treated cows.² The agency was concerned that “rBST-free” labeling implied a health difference that the evidence did not support.

Nonetheless, the label proved to be a powerful marketing tool. Research on consumer behavior found that what drove people to buy rBST-free milk was not the price difference between labeled and unlabeled options but the simple availability of labeled milk. When rBST-free milk was available, people bought it, and interestingly, its presence on store shelves actually reduced the perception of risk associated with rBST-containing milk among all shoppers, including those who did not choose the labeled product.¹⁵ The psychology at work is that having a choice reduces the feeling of being involuntarily exposed to a risk, even if the risk itself has not changed.

Research on risk perception found that the biggest drivers of consumer concern about rBST were not factual beliefs about health effects but what researchers call “outrage factors.” Feeling like you had no choice in the matter, not trusting the FDA as an information source, and seeing no personal benefit from the technology all heightened how risky people perceived rBST milk to be.¹⁶ This helps explain why the debate has been so durable: the concern is not purely about toxicology but about trust, control, and the feeling that a technology benefits farmers and corporations rather than the person drinking the milk.

The Environmental Angle

One argument for rBST that rarely makes it into consumer discussions is environmental efficiency. Because treated cows produce more milk per unit of feed, rBST effectively shrinks the resource footprint of each gallon. A modeling study estimated that supplementing one million cows with rBST would reduce the amount of feed, water, cropland, nitrogen and phosphorus runoff, greenhouse gas emissions, and fossil fuel needed compared to producing the same quantity of milk from unsupplemented cows.¹⁷ Essentially, you can get the same amount of milk with fewer cows and fewer inputs.

This does not settle the welfare or consumer-trust questions, but it adds a dimension that most shoppers are unaware of. In an era when the environmental footprint of animal agriculture is under increasing scrutiny, the efficiency gains from rBST represent a genuine trade-off rather than a straightforward good-versus-bad narrative.

How Regulators and Researchers Test for rBST Use

One of the practical challenges in enforcing rBST-free claims is that the synthetic hormone is nearly identical to the natural version cows produce. You cannot simply test a glass of milk for rBST the way you might test for a pesticide residue, because the molecule you are looking for is also made by the cow’s own body. This has made detection a long-running analytical challenge.¹⁸

Researchers have developed indirect approaches to get around this problem. One method detects antibodies that a cow’s immune system produces in response to rBST injections, since the natural hormone does not normally trigger an antibody response. A screening assay based on this approach found that about two-thirds of rBST-treated cows developed detectable antibodies, and when milk from multiple cows was pooled together (as it is in commercial tank milk), over 95% of samples from treated herds tested positive.¹⁹ Another strategy uses a combination of protein biomarkers, including osteocalcin and anti-rBST antibodies, to correctly identify 95% of treated samples from the second injection onward and even after treatment ended.²⁰

These tools matter most in countries where rBST use is banned and regulators need to verify compliance. In the United States, where rBST remains legal, the testing infrastructure exists mainly for trade purposes and for verifying voluntary “rBST-free” claims made by producers and processors.

Economic Pressures on Dairy Farms

The market dynamics around rBST have been quietly consequential for the structure of the dairy industry. In the United States, many major processors and retailers moved to rBST-free sourcing over the past two decades, driven less by regulatory mandate than by consumer demand and brand positioning. This effectively made rBST use a liability for producers who sold to those buyers, even though the product remained legal and approved.

Economic modeling of rBST’s impact in other countries has shown that approval tends to benefit larger farms while putting smaller operations at a disadvantage. In Japan, simulations projected that rBST approval would accelerate consolidation, with smaller farms facing higher costs, lower profit margins, and lower adoption rates.¹⁴ The technology’s per-cow economics favor operations that can absorb the cost of the hormone and the management changes needed to handle higher-producing cows. For smaller producers, the investment may not pencil out, and the resulting price pressure from competitors who do adopt can squeeze margins further.

In practice, the U.S. market has moved substantially away from rBST use even without a ban. The combination of processor requirements, retail labeling trends, and consumer preferences has made rBST-free production the default for a growing share of the dairy industry. The hormone remains approved and available, but its footprint has shrunk considerably from its peak adoption in the early 2000s, illustrating how market forces can accomplish what regulation did not.